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Background: Cortidis rhizoma (Huanglian) and its major therapeutic component, berberine, have drawn extensive
attention in recent years for their anti-cancer properties. Growth inhibitory effects of berberine on multiple types of
human cancer cells have been reported. Berberine inhibits invasion, induces cell cycle arrest and apoptosis in
human cancer cells. The anti-inflammatory property of berberine, involving inhibition of Signal Transducer and
Activator of Transcription 3 (STAT3) activation, has also been documented.
Methods: In this study, we have examined the effects of berberine on tumorigenicity and growth of nasopharyngeal
carcinoma (NPC) cells and their relationship to STAT3 signaling using both in vivo and in vitro models.
Results: Berberine effectively inhibited the tumorigenicity and growth of an EBV-positive NPC cell line (C666-1) in
athymic nude mice. Inhibition of tumorigenic growth of NPC cells in vivo was correlated with effective inhibition
of STAT3 activation in NPC cells inside the tumor xenografts grown in nude mice. In vitro, berberine inhibited both
constitutive and IL-6-induced STAT3 activation in NPC cells. Inhibition of STAT3 activation by berberine induced
growth inhibition and apoptotic response in NPC cells. Tumor-associated fibroblasts were found to secret IL-6 and
the conditioned medium harvested from the fibroblasts also induced STAT3 activation in NPC cells. Furthermore,
STAT3 activation by conditioned medium of tumor-associated fibroblasts could be blocked by berberine or
antibodies against IL-6 and IL-6R.
Conclusions: Our observation that berberine effectively inhibited activation of STAT3 induced by tumor-associated
fibroblasts suggests a role of berberine in modulating the effects of tumor stroma on the growth of NPC cells. The
effective inhibition of STAT3 activation in NPC cells by berberine supports its potential use in the treatment of NPC.Background
Traditional Chinese medicine represents a rich reservoir
of potential small chemical molecules exhibiting anti-
cancer properties [1]. Various natural products isolated
from medicinal plants and their derivatives such as
vinca alkaloid, etoposide, paclitaxel etc., are currently used* Correspondence: yfeng@hku.hk; gswtsao@hku.hk
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reproduction in any medium, provided the orsuccessfully in cancer treatment [1,2]. The growth inhibi-
tory effects of berberine have been recently reported in
several types of human cancer cells, including hepato-
celluar carcinoma, lung adenocarcinoma and breast
cancer [3-5]. Berberine is an isoquinoline alkaloid and
belongs to the structural class of protoberberines [6]. It is
present in the roots, rhizome, and stem bark of a number
of important medicinal plant species including Cortidis
rhizoma (Huanglian), Berberis vulgaris (barberry), Coptis
chinensis (Chinese goldthread), and Scutellaria baicalensis
(Baikal Skullcap), all of which have been used as trad-
itional or folk medicines for centuries in China, India,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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growth of various types of cancer cells by inhibiting DNA
topoisomerase I, inducing cell-cycle arrest and apoptosis
through Fas/FasL signaling pathways and activation of
caspase-3 [7]. In addition to their prominent anti-cancer
activities, Berberine also exerts anti-inflammatory activ-
ities and inhibitory effects on growth and reproduction
of tumorigenic microorganisms and viruses, such as
Helicobacter pylori and hepatitis B virus [6,8]. We have
previously reported that berberine can suppress the in-
vasive properties of nasopharyngeal carcinoma (NPC)
cell lines through inhibiting the activities of Rho
GTPases [9]. Previous studies have also reported that
berberine can suppress metastasis by enhancing the
expression of a metastasis suppression gene, NM23-H1,
or by targeting Rho kinase-mediated ezrin phosphoryl-
ation in NPC 5-8 F cell line [10,11]. In another study, we
reported that berberine induces autophagic cell death and
mitochondrial apoptosis in liver cancer cells [12]. Effective
application of berberine as combined medication for
tumor treatment has been reported [13,14]. Synergistic
anti-tumor effects were also observed when berberine and
irradiation were used in combination to treat lung cancer
in both in vivo and in vitro models [14]. Another study
indicated that berberine could enhance the anti-cancer
effects of estrogen receptor antagonists on human breast
cancer cells (MCF-7) through downregulating the ex-
pression of EGFR, HER2, Bcl-2, and COX-2, as well as
upregulating IFN-α and p21 [13].
With this wide spectrum of anti-tumor properties,
berberine has potential application as a complementary
medicine for treatment and possibly prevention of human
cancers. NPC is common among southern Chinese or
Southeast Asian with an incidence rate of ∼ 30/100 000
per year in endemic regions such as Hong Kong and
Guangzhou [15,16]. Besides its strong ethnic association
with Southern Chinese, several epidemiological studies
demonstrated that other risk factors are involved including
Epstein-Barr virus infection, familial history, specific hu-
man leukocyte antigen (HLA) haplotype and male gender
[16]. EBV infection is closely associated with undifferenti-
ated type of NPC, which is the common histological type
of NPC in southern Chinese, and has been postulated as
an important etiological agent for NPC pathogenesis
[16-18]. The majority of NPC patients (60–70%) are
commonly presented with advanced diseases (Stages III
and IV) at time of diagnosis. Despite the effective treat-
ment by radiation and chemotherapeutic treatment, more
than one third of NPC patients develop recurrence, some
with distant metastasis [15].
Current research progress has revealed that the Signal
Transducer and Activator of Transcription 3 (STAT3)
plays a pivotal role in NPC development [19]. Activation
of STAT3 may contribute to both development andprogression of NPC. STAT3-mediated oncogenesis can be
attributed by the transcriptional upregulation of multiple
downstream effector genes in cancer cells such as Mcl-1,
which can promote cell growth, survival, and angiogenesis
[20,21]. Our previous study also demonstrated a direct
contribution of STAT3 activation to the invasive property
of NPC cells [22]. STAT3 is activated in the majority of
NPC patients (>75% of cases) and clinically correlated
with advanced disease (stages III and IV) [23]. Thus, tar-
geting aberrant STAT3 signaling may provide an effective
and novel strategy for treatment of NPC [19].
Despite the fact that STAT3 activation is common in
NPC, the mechanisms of STAT3 activation in NPC has
not been fully elucidated. Cytokine-mediated STAT3 acti-
vation is believed to be a major mechanism driving STAT3
activation in several types of epithelial cancer [21]. As a
matter of fact, development of NPC may be dependent on
a highly inflammatory stroma. The tumor-infiltrating fi-
broblasts, macrophages, and lymphocytes release a myriad
of inflammatory cytokines to support and maintain the
growth and malignant properties of tumor [16]. Interleu-
kin 6 (IL-6), a potent cytokine for STAT3 activation, was
elevated in the sera of around 70% of NPC patients (out of
314 NPC patients) [24]. This elevation of serum IL-6 was
also associated with the advanced diseases and the adverse
prognosis of NPC. All these suggest that modulation of
inflammatory responses in NPC by regulating the release
of IL-6 and inhibition of STAT3 activation may suppress
the development and growth of NPC.
Given the importance of STAT3 and inflammation in
NPC pathogenesis, we set out to examine whether ber-
berine could suppress activation of STAT signaling to
exhibit anti-cancer effects using in vitro and in vivo
models. Interestingly, we demonstrated for the first time
that berberine could suppress the tumorigenic growth
of NPC cells in athymic nude mice and inhibit the
STAT3 activation. Berberine could also inhibit constitu-
tive activation of STAT3 and its downstream effector,
Mcl-1 in NPC cells. Furthermore, berberine also inhib-
ited the activation of STAT3 by IL-6 in NPC cells. We
also found that IL-6 secreted by tumor-associated fibro-
blasts could upregulate STAT3 activation in NPC cells
in culture. By pre-treatment of the NPC cells with ber-
berine, activation of STAT3 induced by tumor-derived
fibroblasts was suppressed. Taken together, our results
suggest that berberine may be a potential product from
medicinal plant which can effectively inhibit the growth
of NPC through suppression of STAT3 signaling.
Methods
Chemicals and antibodies
Berberine Chloride (C20H18ClNO4) was purchased from
Sigma Chemicals (St. Louis, MO, USA). It was dissolved
in sterile milli-Q water at a 80°C water bath for 10 mins
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before use. The primary antibodies used to detect p-
STAT3 (Tyr 705), STAT3, cleaved-PARP-1, and β-actin
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Antibody for detecting cytokeratin (clones
AE1/AE3) was purchased from Dako (Carpinteria, CA,
USA). The antibodies to detect Mcl-1, IL-6 (clone H-183)
and the horseradish peroxidase (HPR)-linked secondary
antibodies goat anti-mouse and goat anti-rabbit IgG were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). IL-6 and anti-IL-6-receptor antibody were
purchased from R&D system (Minneapolis, MN, USA).
Cell culture
C666-1 is a subclone of its parental cell line, C666, de-
rived from an undifferentiated NPC xenograft of southern
Chinese origin [25]. HONE-1 is derived from a poorly
differentiated NPC from Chinese patient [26]. HK1 was
established from a recurrent well-differentiated NPC of
a Chinese patient after radiation therapy [27]. C666-1,
HONE1 and HK1 cells were cultured in RPMI-1640
medium (Sigma) supplemented with 10% fetal bovine
serum (FBS) (Sigma), 100 μg/ml penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA) and maintained at 37˚C
in a humidified atmosphere of 5% CO2. NP460 is an im-
mortalized nasopharyngeal epithelial cell line established
in our laboratory [28]. It is a non-tumorigenic cell line de-
rived from normal nasopharyngeal tissue. It was cultured
in a 1:1 mixture of Defined Keratinocyte-SFM (Invitrogen)
and EpiLife™ medium with full supplements (Invitrogen).
Tumour-associated fibroblasts were derived from primary
cultures of NPC biopsies. Prior patient consents were ob-
tained for the use of biopsied tissues for research investi-
gation. The collection and use of the specimen have been
approved by the Human Research Ethic Committee of
the University of Hong Kong. The sample was collected
in Queen Mary Hospital in Hong Kong. The NPC tissue
was cut into small pieces (1 mm3) and left to grow in
RPMI-1640 medium (Sigma) supplemented with 10%
FBS (Sigma). After one week, the fibroblasts grew out
from the NPC biopsies will be frozen down in liquid
nitrogen for future use.
In vivo nude mouse tumorigenicity assay
The in vivo nude mouse tumorigenicity assay was per-
formed by injecting a total of 1 X 106 C666-1 cells sub-
cutaneously into the flank of 6–8 week old male nude
mice. At the same day of injection of tumor cells, the
drug was then administrated into the mice intraperito-
neally (i.p.). The mice were either injected with saline
(control group) or with berberine concentrations of
5 mg/kg body weight (low dose group) and 10 mg/kg
body weight (high dose group) every other two days.
Once tumor growth was established in the control mice(i.e. 14 days post-injection of tumor cells), tumor sizes
were measured every other day. Tumor volume (mean ±
SD) was calculated as length x width2/2 [29].
Western blot analysis
Cell lysates were collected by scraping the cells with RIPA
lysis buffer from the culture dishes, and the protein con-
centrations were determined using the DC Protein Assay
Kit (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s protocol. Equal amount of protein lysate
(20 μg) per sample was resolved on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto a polyvinylidene fluoride (PVDF)
membrane (Amersham, Piscataway, NJ, USA). Membranes
were probed with desired primary antibodies followed by
detection of chemiluminescent signals of the peroxidase-
conjugated secondary antibody using ECL Plus Western
blotting detection system (Amersham, Buckinghamshire,
UK). β-actin was used as an internal control to verify basal
expression levels and equal protein loading. The ratio of
the specific proteins to β-actin was calculated.
Immunohistochemistry
Subcutaneous tumors developed in nude mice were ex-
cised on 43 days post-injection of C666-1 cells. Sections
for immunohistochemistry were dewaxed in xylene and
rehydrated in graded alcohol. Endogenous peroxidase
activity was blocked by incubating slides with 3% hydro-
genous peroxide for 10 min. For antigen retrieval, all
slides were incubated with 10 mmol/L citrate buffer
(pH 6.0) for 93°C for 10 min, and then cooled down to
room temperature. After that, the sections were rinsed
with PBS and treated with normal blocking serum (Vector
Laboratories, Inc., Burlingame, CA, USA) for 30 min.
Anti-p-STAT3 (1:100, Cell signaling) and anti-cytokeratin
antibodies (1:200, Dako) diluted in PBS were applied to
the sections and incubated at 4°C overnight. After rins-
ing, all sections were further incubated for 1 hr with
biotin-conjugated secondary antibody and horseradish
peroxidase-conjugated streptavidin followed by using
diaminobenzidine (Dako) as a chromogen. Counterstain-
ing was performed by hematoxylin before dehydration and
mounting.
ELISA for IL-6
The concentrations of IL-6 secreted from the NPC fibro-
blasts were quantitated using ELISA assay for IL-6 (R&D
Systems) according to manufacturer instructions. Tripli-
cated samples were estimated and the averages were used
in the analysis.
MTT assay
The effect of berberine on cell viability/ proliferation was
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-
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lium salt, is reduced to a purple blue formazan product by
dehydrogenases in the mitochondria of living cells. The
cell viability can thus be determined by quantifying the
purple blue formazan product based on UV absorbance.
Briefly, 5000 cells/well were plated in 96-well plates and
incubated for 24 h. The cells were then treated with ber-
berine at indicated concentrations for 24, 48 and 72 hr.
The cells were then treated with 10 μl of 5 mg/ml MTT
(Sigma) and incubated for 4 hr at 37˚C. The medium was
then discarded, and 200 μl of dimethyl sulfoxide (DMSO)
(Sigma-Aldrich, MO, USA) was added to dissolve the
resulting formazan crystals. The absorbance was measured
at 570 nm by the Multiskan MS microplate reader
(Labsystems, Finland) with a blank reference at 650 nm.
Statistical analysis
The data from each experiment were expressed as mean ±
standard deviation (SD). Student’s t test was used to assess
the differences between experimental groups. A p value <
0.05 was considered as statistically significant throughout
this study.
Ethical approval
The use of animals in this study was approved by the
Committee on the use of live animals in teaching and
research, the University of Hong Kong, Hong Kong.
Results
Berberine suppressed tumorigenicity and growth of NPC
cells in nude mice
Corptis rhizoma is commonly used in several treatment
remedies for cancer and berberine is the major active in-
gredient extracted from it [6,7]. In vitro inhibition of
growth of human cancer cells by berberine has been re-
ported by multiple studies [7]. It is crucial to examine any
anti-tumor effects of natural product using in vivo tumor
models. In this study, we have first assessed whether ber-
berine could suppress the tumorigenic growth of NPC
cells in immune deficient mice. The C666-1 cell line used
for in vivo investigation harbours EBV infection which is
representative of NPC from southern Chinese. To exam-
ine for inhibition of tumorigenicity and growth in vivo,
1 X 106 C666-1 cells were injected subcutaneously into
the flank of nude mice. On the same day of injection,
the mice were either injected intraperitoneally (i.p.) with
saline or low or high doses of berberine (5 mg/ and
10 mg/kg respectively) every two days. In the control
mice (saline-treated), tumors started to appear after
14 days post-injection, and substantial growth of the
tumor masses could be observed (Figure 1a). However,
no measurable tumor masses could be detected in the
berberine-treated mice until 30 days after injection of
tumor cells in the 5 mg/kg berberine treatment groupand 43 days in the 10 mg/kg berberine treatment group
respectively (Figure 1a). By examination of the growth
curves of individual tumor developed in control and
berberine-treated groups, we could clearly observe a
steady increase of tumor size in 4 out of 4 mice in control
group after 14 days post injection (Figure 1b). Significant
inhibition of in vivo tumorigenic growth of C666-1 was
observed in both berberine treatment groups (5 mg/kg
and 10 mg/kg). In treatment group injected with berberine
(5 mg/kg), tumor growth was detected at 31 ± 5 days post-
injection. In treatment group injected with higher dose
(10 mg/kg), tumor growth was detected at 37 ± 5 days post
infection (Figure 1b). Furthermore, tumorigenic growth of
C666-1 was observed in only 2 out of 5 mice injected with
10 mg/kg (Figure 1b). These data suggest that berberine
effectively suppresses the establishment and subsequent
tumorigenic growth of NPC cells in vivo. Berberine is a
natural compound found in traditional Chinese medicine
and generally regarded as having low toxicity. Nonethe-
less, we have examined if there are any toxicity induced in
berberine-treated mice in terms of mortality of the ani-
mals and alteration in body weight. The body weight and
well-being of the control and berberine-treated mice were
monitored periodically starting from day 1 of berberine
administration. We did not observe significant alteration
of body weight, morbidity and mortality after berberine
treatment (Figure 1c). These results confirmed the find-
ings from other reports stating that berberine is low in
toxicity and does not induce adverse or detrimental effects
on the general healthiness of mice.
Berberine suppressed activation of STAT3 in NPC
xenografts grown in nude mice
Constitutive activation of STAT3 was commonly observed
in NPC tissues and was known to promote growth, sur-
vival and progression of NPC [19,22,23]. In this study, we
examined if berberine may suppress STAT3 activation in
NPC grown as xenografted tumor in nude mice. The
C666-1 NPC cells grown as subcutaneous tumor har-
vested from mice in control and treatment groups were
embedded in paraffin, sectioned, and examined by immu-
nohistochemical staining. Activated STAT3 will undergo
phosphorylation and translocate to cell nucleus. Using
antibody specific for phosphorylated STAT3 (p-STAT3),
activated STAT3 could be demonstrated as brown nuclei
stain in the tumor cells (Figure 2). We have also per-
formed staining using antibody against cytokeratin to
identify the C666-1 cells (epithelial in origin) from the
stromal cells. For each section of tumors harvested from
control and treatment groups, 5 random microscopic
fields which contain over 95% of C666-1 cells were chosen
for examination. The percentages of STAT3-activated
C666-1 cells were counted. The tumor sections in the
control group revealed 75% ± 12.6 of positive staining of
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Figure 1 Suppression of tumorigenicity and growth of NPC cells by berberine in vivo. (a) Berberine could suppress the tumor initiation
and growth of C666-1 xenografts in mice models. 1 X 106 Tumor cells were injected subcutaneously into nude mice. Mice were either treated
with berberine (low dose: 5 mg/kg or high dose: 10 mg/kg; i.p.) or treated with saline (as control) for every other two days. Both low and high
dose of berberine could significantly suppress the tumor growth (p < 0.05) when compared to that of the control mice. (b) Individual growth
curves of tumors in control and berberine-treated mice. The tumor sizes of individual mouse under control treatment (PBS-treated; n = 4), under
low dose of berberine treatment (5 mg/kg berberine-treated; n = 5) and under high dose of berberine treatment (10 mg/kg berberine-treated;
n = 5) were followed from 14 to 43 days post-injection of tumor cells. (c) The body weights of the mice within the treatment and control groups
were comparable. The weights of the mice were recorded from the day of injection until 43 days post-infection of tumor cells. Both the control
mice and berberine-treated mice showed a steady increase of body weight. Both 5 mg/kg and 10 mg/kg treatment of berberine did not cause
drastic variation of body weight to the mice.
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cells were stained positive for p-STAT3 in the treatment
groups injected with 5 mg/kg and 10 mg/kg of berberine
respectively (p <0.05). Representative images showing the
effective downregulation of p-STAT3 in the xenografted
tumors treated with 5 mg/kg and 10 mg/kg of berberine
are shown (Figure 2).
Berberine suppressed the STAT3 signaling in NPC cell line
in vitro
We then examined if berberine could suppress STAT3
in NPC cell grown in vitro. We first examined STAT3activation in C666-1. Interestingly, STAT3 activation was
not prominent in C666-1 grown in culture despite of its
strong activation when grown in vivo. We postulated that
STAT3 activation in C666-1 grown as xenograft may be
induced by inflammatory signals from the host stroma.
We have also investigated the effects of berberine on
HONE1 which is an NPC cell line with high level of con-
stitutive activation of STAT3 (Figure 3). High expression
of p-STAT3 was detected in HONE1 cells. We observed
that berberine could effectively suppress the level of
p-STAT3 in HONE1 cells (Figure 3). Furthermore, the
downregulation of STAT3 activation was associated
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Figure 2 Activation of STAT3 was inhibited by berberine in vivo. Mice were continuously treated with saline (control group), low dose of
berberine (5 mg/kg) and high dose of berberine (10 mg/kg) for every other two days up to a period of 43 days. The mice were then sacrificed
and the tumors were sectioned and detected for p-STAT3. The sections were also stained with cytokeratin antibodies to identify the C666-1 cells
from the fibroblasts. 5 random microscopic fields which consist of more than 95% of C666-1 cells were chosen for examination. Both low and
high dose of berberine could significantly suppress the activation of STAT3 (p < 0.05) in C666-1 cells when compared to the controls.
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survival protein of STAT3) and an increased level of
cleaved PARP-1 (an apoptotic marker) (Figure 3). This in-
dicates that berberine could suppress constitutive activa-
tion of STAT3 in NPC cells and inhibited their survival
ability by activating apoptosis.BBR (µM)
HONE1
Stat 3
Cleaved 
PARP
Mcl-1
p-Stat 3
0    25      50 
β-actin
Figure 3 Constitutive activation of STAT3 was downregulated
by berberine in HONE1 cells. HONE1 cells were treated with 25
and 50 μM berberine for 24 h. The activation of STAT3 was strongly
suppressed by the treatment of berberine with a downregulation of
survival protein (Mcl-1) and upregulation of apoptotic protein
(cleaved-PARP-1). β-actin was probed for loading controls.IL-6-mediated STAT3 activation in NPC cells was inhibited
by berberine
Next, we examined if activation of STAT3 by extracellu-
lar stimulus, such as IL-6, could also be suppressed by
berberine. IL-6 is one of the major inflammatory cyto-
kine present in NPC tissues. It has been reported that
there is a positive feed-back loop of IL-6/STAT3 signal-
ing in NPC to potentiate STAT3 signaling which en-
hances malignant properties of NPC [30]. In this study,
IL-6 (20 ng/ml) was added to two NPC cell lines (C666-1
and HK1), which have low basal level of STAT3 activation,
for 0, 4 and 6 hr in the presence or absence of 50 μM of
berberine. Figure 4 shows that expression of p-STAT3
in both cell lines could be induced by IL-6 in a time-
dependent manner. Berberine could effectively suppress
the IL-6-induced p-STAT3 in both NPC cell lines
(Figure 4).
Berberine exhibited low toxicity towards cell lines with
low basal activation of STAT3
We have previously demonstrated that berberine could
potently suppress the IL-6-induced or constitutive acti-
vated STAT3 in NPC cells. We speculated that berberine
may be able to target cancer cells which are dependent on
STAT3 activation for growth and survival. We performed
MTT assays to assess the cytotoxicity of berberine on
three NPC cell lines (HK1, C666-1 and HONE1) and also
one normal immortalized nasopharyngeal epithelial cell
line (NP460) . Interestingly, berberine had high toxicity to-
wards the HONE1 cell line, which has constitutively acti-
vated STAT3 (Figure 5). The IC50 after 24 hr berberine
treatment for HONE1 was around 100 μM, while the
IC50 after similar treatment for HK1, C666-1 and NP460
was around 400 μM (Figure 5).
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Figure 4 Berberine inhibited the IL-6-activated STAT3 in C666-1
and HK1 cells. Western blots analysis of (a) C666-1 and (b) HK1
cells with or without addition of berberine (50 μM) after IL-6
treatment (20 ng/ml) for 0, 4 and 6 hr. The cell lysate was probed
with anti-STAT3 and anti-p-STAT3. Equal protein loading was
established with anti-β-actin antibody.
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Figure 5 Berberine exhibited higher toxicity towards HONE1
cells. MTT assays were performed on one non-neoplastic
nasopharyngeal epithelial cell line (NP460), and three NPC cell lines
(HK1, C666-1 and HONE1) for 24, 48 and 72 hr under the indicated
doses of berberine (0, 50, 100, 200, 400 and 800 μM). For each time
point, the growth rates of each untreated cell line were arbitrarily
assigned as 100. Mean ± SD were calculated from triplicate of two
independent experiments.
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could be inhibited by berberine
In vivo, fibroblasts in tumor tissue have been postulated
to serve as a source of pro-oncogenic cytokines, including
IL-6 [31]. Here, we used fibroblasts isolated from primary
human NPC tumor biopsy to develop an in vitro system
to mimic the in vivo secretion of IL-6 by stromal cells and
the subsequent activation of STAT3 in cancer cells. The
primary fibroblasts derived from NPC tissue were cultured
in serum free medium for 4 days and culture supernatants
from day 1 to day 4 were collected for investigation.
The concentrations of IL-6 in the culture supernatants
were measured by ELISA, and was found to progres-
sively increase to a concentration of around 1,500 pg/ml
at day 4 (Figure 6a). This concentration of IL-6 was suf-
ficient to stimulate STAT3 activation in C666-1 cells.
STAT3 activation as indicated by the phosphorylation
of STAT3 was induced at a time-dependent manner in
C666-1 cells after incubation with fibroblast-conditioned
medium (Figure 6b). The STAT3 activation in the NPC
cells by fibroblast-conditioned medium could be sup-
pressed by treating the cells with 50 μM berberine
(Figure 6c). To further confirm that IL-6 in the fibroblast-conditioned medium was involved in the activation of
STAT3 in C666-1 cells, anti-IL-6 and anti-IL-6-receptor
antibodies were added to the fibroblast-conditioned
medium. Both antibodies could effectively inhibit the acti-
vation of STAT3 (Figure 6d). It could be deduced that IL-
6 secreted from fibroblasts play a key role in the activation
of STAT3 in C666-1 cells and activation of IL-6-receptor
on NPC cells was involved. Furthermore, IL-6 treatment
also increased the growth rate of C666-1 cells (Figure 6e).
Discussion
There are ample evidences supporting a functional role of
STAT3 in tumorigensis and progression of NPC through
promotion of tumor initiation, growth and invasive prop-
erties of cancer cells [19,22,32]. STAT3 activation emerges
as a potential target for therapeutic treatment of NPC
[19]. In this study, we found that berberine could effect-
ively inhibit the growth of NPC xenografts in nude mice
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be involved (Figure 2). In vitro experiments provide evi-
dences that the inhibitory action of berberine on NPC
cells could be mediated by directly inhibiting the consti-
tutive activation of STAT3 or by inhibiting the STAT3
activation induced by exogenous pro-inflammatory cyto-
kines such as IL-6 (Figures 3, 4, 5, 6).
Several studies have shown that STAT3 is a potential
target for anti-cancer therapy [19,21,33]. Treatment with
STAT3 inhibitor selectively suppressed the growth, via-
bility, survival and malignant transformation of human
breast (MDA-MB-231) and pancreatic (Panc-1) cancer
lines, and down-regulated the expression of known
STAT3-regulated genes, including c-Myc, Bcl.xL, the
matrix metalloproteinase 9, and VEGF [34]. It could
induce strong tumor regression in xenografts of the
human breast cancer [35]. Furthermore, recent evidences
indicate that STAT3, apart from being a target for anti-
cancer therapy, may also represent a crucial target for can-
cer prevention as STAT3 plays an essential role in tumor
formation and initiation [32,35]. STAT3-deficient mice
were completely resistant to skin tumor development in a
chemical-induced skin tumorigenesis model [36]. Further-
more, in breast cancer, abrogation of STAT3 activation
inhibited tumor formation in the mammary fat pad of a
syngeneic model [37]. In NPC, one of our previous publi-
cations also showed that brief exposure of tumor cells with
JAK/STAT3 inhibitor could efficiently suppress the tumor
initiation in nude mice [32]. In this study, we demonstrate
the suppressive effect of tumor growth by berberine
through inhibiting STAT3 activation. Berberine has been
administrated into human bodies for a history of thousands
of years with few indications of serious adverse effects. In
an early study, berberine was shown not to cause any
histopathological changes in rat tissues and organs when
administered for 6 weeks in 500 mg/kg daily oral doses
[38]. We also observed that the berberine-treated mice did
not suffer from loss of body weight when compared to
PBS-treated mice (Figure 1c). The low toxicity of berber-
ine and its effective inhibition of STAT3 and tumorigenic
growth of NPC make it a potential anti-cancer drug or
even chemopreventive agent for NPC through its inhibi-
tory effects on inflammation which is common in prema-
lignant and cancerous NPC tissues.
We have further examined the inhibitory effect of berber-
ine against STAT3 activation using various NPC cell lines
grown in vitro. One of our NPC cell lines, HONE1, is consti-
tutively activated in STAT3 without the need of extracellular
stimulus. Berberine was shown to effectively suppress the
constitutive activation of STAT3 in HONE1 cells (Figure 3).
The downstream effector of STAT3, Mcl-1 (a survival pro-
tein) was also significantly downregulated by berberine
treatment which was accompanied by upregulation of
cleaved-PARP-1 (apoptosis marker) (Figure 3).The underlying reason for common STAT3 activation
in NPC is not completely defined. EBV infection, and
stimulation with cytokines from inflammatory stroma
may activate STAT3 in NPC [19,39]. We have investi-
gated if berberine could inhibit STAT3 activation in
NPC cells by exogeneous stimulus, IL-6, which is com-
monly secreted by inflammatory stroma cells present in
tumor microenvironment. Elevation of serum IL-6 was
detected in more than 70% of NPC patients [24]. An
earlier study has indicated the involvement of STAT3
in mediating the IL-6/LMP1 feedback in LMP-1-
expressing cell or EBV-infected cells [30]. In our recent
study, we reported long-term propagation of EBV
infection in nasopharyngeal epithelial cells enhances
IL-6-mediated STAT3 activation [39]. Hence, EBV in-
fection in NPC may potentiate the activation of STAT3
in infected cells under an inflammatory stroma, in
which IL-6 is highly expressed. In the present study, we
found that both C666-1 (an EBV-infected NPC cell
line) and HK1 (a non-infected NPC cell line) which
have low basal level of STAT3 activation, were respon-
sive to exogenous STAT3 activation by IL-6. Berberine
was shown to potently suppress the IL-6-activation of
STAT3 in both cell lines (Figure 4). By performing MTT
assay on C666-1, HK1, HONE1 and immortalized
NP460 cells, we found that berberine has low toxicity
towards the cells with low basal levels of activated
STAT3, but has higher toxicity towards HONE1 cell
line, which has constitutively activated STAT3 (Figure 5).
The much lower IC50 of HONE1 compared to the other
cell lines may reflect its dependency for STAT3 activa-
tion for growth and survival. This also suggests that the
suppressive effect of berberine on the tumorigenicity of
C666-1 in nude mice might due to its inhibition on
STAT3 activation when grown in vivo. To mimic the
in vivo activation of STAT3 in tumor cells with cyto-
kines secretion from stroma cells in tumor, we used the
fibroblast-conditioned supernatant to induce STAT3
activation in NPC cells (Figure 6a and b). Berberine
was able to suppress the STAT3 activation in NPC cells
induced by fibroblast supernatant and inhibition of IL-
6-induced STAT3 activation was involved (Figure 6c
and d). At last, IL-6 could enhance the growth of NPC
cells in vitro (Figure 6e). All these results support a
novel role of berberine to inhibit STAT3 signaling in
NPC by targeting fibroblasts present in tumor stroma.
Besides, STAT3 mediated pro-oncogenic inflammation
has also been well documented to promote tumor ini-
tiation and progression [40,41]. In view of the effective
action of berberine to inhibit STAT3 and relatively
low toxicity, berberine may serve as an effective che-
mopreventive agent or conjugant medicine for treat-
ment of NPC through modulating the inflammatory
tumor microenvironment.
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Berberine could suppress the growth and activation of
STAT3 of NPC cells in vivo. It could also inhibit both
the constitutive and IL-6-induced STAT3 activation
in vitro. Higher cytotoxicity of berberine was exhibited
in cell line with constitutive activation of STAT3. It sug-
gests that berberine can suppress the growth and survival
of NPC cells which are dependent on STAT3 activation
for tumorigenicity. Besides, berberine could abrogate
the activation of STAT3 in NPC cells induced by the IL-6
secreted from tumor-associated fibroblasts. All these
support the potential use of berberine in the treatment
of NPC.
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